Newly-Named KaloBios Pharma (KBIO) CEO Shkreli Briefly Comments on Twitter About Appointment

KaloBios Pharma (KBIO) Receives NASDAQ Delisting Notice

The NASDAQ Stock Market notified KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), by letter dated November 17, 2015, that the Company is not currently in compliance with Nasdaqs continued listing requirement set forth in Rule 5250(c)(1) of the Nasdaq Listing Rules (the Rules), due to its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the 2015 Third Quarter 10-Q) with the Securities and Exchange Commission (the SEC).

Under the Rules, the Company has 60 calendar days from November 17, 2015 to submit a plan to Nasdaq to regain compliance with the Rules. The Company intends to file... More

Macrocure (MCUR) Ramps Higher

Macrocure (NASDAQ: MCUR) shares advanced Friday, rising 50%. Some traders tied the moved to recent gains in KaloBios Pharma (NASDAQ: KBIO) and Macrocure's 'thin' 6.2 million share float.

KaloBios Pharma (KBIO) Names Martin Shkreli as CEO

KaloBios Pharma (NASDAQ: KBIO) announced that an investor group led by Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares. KaloBios also announced the appointment of Martin Shkreli to the position of Chief Executive Officer and his election as Chairman of the Board. In his new role, Mr. Shkreli will work with the company's senior management team to ensure the Company's continued operations. KaloBios further announced that David... More

Needham & Company Drops Coverage of KaloBios Pharma (KBIO)

Needham & Company dropped coverage of KaloBios Pharma (NASDAQ: KBIO).

Analyst Alan Carr commented, "Kalobios announced last week plans to wind down operations and liquidate company assets. Management had expressed concern at the time that it was unlikely efforts to explore strategic... More